PT  - JOURNAL ARTICLE
AU  - Kiptim, Peter Kibet
AU  - Kariuki, Rahab Wangari
AU  - Kimonge, Damaris
TI  - Comparison Of Low-Density Lipoprotein Cholesterol (Ldl-C), Atherogenic Index In Plasma (Aip) And Apolipoprotein B/Apolipoprotein A1 Ratio In Patients Sent For Routine Lipid Profile Testing At Biochemistry Laboratory - Kenyatta National Hospital
AID  - 10.1101/2023.10.25.23297527
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.10.25.23297527
4099  - http://medrxiv.org/content/early/2023/10/25/2023.10.25.23297527.short
4100  - http://medrxiv.org/content/early/2023/10/25/2023.10.25.23297527.full
AB  - Background Cardiovascular disease is a rising global concern accounting for one-third of mortalities. Notably, cardiovascular disease risk factors; including dyslipidemia, smoking, obesity, poor diet, and hypertension are modifiable. It has been established through various studies that dyslipidemia is at the core of atherosclerosis observed in cardiovascular diseases making it important in risk assessment and as a therapeutic target as informed by various guidelines. Plasma lipid profile has been key in the diagnosis of dyslipidemia particularly low-density lipoprotein cholesterol that is used in initial risk assessment and treatment monitoring. However, due to clinical and analytical challenges, LDLC is understated or overstated in some patients due to biological variability.Objective To compare low-density lipoprotein cholesterol, atherogenic index in plasma, and Apolipoprotein A1 / Apolipoprotein B ratio for cardiovascular risk assessment in patients sent for routine lipid profile testing at biochemistry laboratory - Kenyatta National HospitalMethodology This was laboratory-based cross-sectional study, 307 residual samples from patients sent for lipid profile testing were tested for, Apo A1, and Apo B concentrations using Mindray BS 2000M chemistry analyzer using Mindray reagents (Shenzhen Mindray Bio-Medical Electronics Co., Ltd) at biochemistry laboratory KNH. The obtained data was used to calculate the atherogenic index of plasma (AIP) and Apo B/ Apo A ratio.Results The median age of the participants was 49 years, 56% were female. The median(range) values were Total cholesterol 4.17 (3.11, 5.20),High-density lipoprotein cholesterol 1.21 (0.88, 1.54)Low-density lipoprotein cholesterol 2.60 (1.84, 3.37)Triglycerides 1.12 (0.83, 1.62),APOA-1 1.38 (1.11, 1.57),APOB 0.95 (0.73, 1.21)Apo B/ApoA-1 ratio 0.75 (0.56, 0.94) and Atherogenic index of plasma 0.09 (−0.14, 0.45). More than a quarter (26.7%) of the participants had LDL-C above 2.35 mmol/l. More than a third of the patients (42%, n=124) were at risk of CVD according to ApoB/ApoA-1 ratio, while 40 %,(n=122) had a high CVD risk according to the atherogenic index stratification.We observed a positive correlation between LDL-C and ApoA-1, Apo B and Apo B/ApoA-1 ratio. There is a significant agreement between atherogenic index and APOB/APOA-1 ratio in CVD risk identification kW=0.36 (95% CI, 0.27-0.46), p<0.001.Conclusion Atherogenic Index of plasma, Apo A and Apo B markers offer additional benefits in CVD risk identification.Competing Interest StatementThe authors have declared no competing interest.Funding StatementYesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by: KNH - UON Ethics and Research Committee. Approval number : P553/06/2022I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll relevant data are within the manuscript and its Supporting Information files.